CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04098068
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:40.831068+00:00
Published At: 2023-05-19T00:00:00+00:00
Record Updated At: 2025-03-30
Results Posted At: 2023-05-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High Tumor Mutation Burden", "High TMB (Tumor Mutation Burden)", "MSS (Microsatellite Stable)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-30"
protocolSection.identificationModule.nctId: "NCT04098068"
protocolSection.identificationModule.officialTitle: "Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-05-19"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.